Table 3 Primary reasons for treatment discontinuation – from chart review
Primary reason for treatment discontinuation | First line (N = 220a) | Second line (N = 236a) | Third line (N = 113a) |
|---|---|---|---|
n, (%) | n, (%) | n, (%) | |
Disease progression | 168 (76.4%) | 169 (71.6%) | 57 (50.4%) |
Total completion of treatment | 31 (14.1%) | 30 (12.7%) | 7 (6.2%) |
Toxicities or side effects | 14 (6.4%) | 8 (3.4%) | 7 (6.2%) |
Patient choice (non-financial) | 4 (1.8%) | 8 (3.4%) | 5 (4.4%) |
Financial reasons | 1 (0.5%) | 1 (0.4%) | 1 (0.9%) |
Drug resistance | 2 (0.9%) | 0 (0.0%) | 1 (0.9%) |
Patient physical status | 0 (0.0%) | 2 (0.8%) | 1 (0.9%) |
Death related to mBC | 0 (0.0%) | 5 (2.1%) | 3 (2.7%) |
Death not related to mBC | 0 (0.0%) | 2 (0.8%) | 1 (0.9%) |
Treatment still ongoing | 0 (0.0%) | 11 (4.7%) | 30 (26.5%) |